Peripheral Arterial Disease (PAD) Therapeutics

Peripheral Arterial Disease (PAD) Therapeutics

Global Peripheral Arterial Disease (PAD) Therapeutics Market to Reach US$7.8 Billion by 2030

The global market for Peripheral Arterial Disease (PAD) Therapeutics estimated at US$4.8 Billion in the year 2023, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Peripheral Stents, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Peripheral Angioplasty Balloons segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 6.6% CAGR

The Peripheral Arterial Disease (PAD) Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.2% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Peripheral Arterial Disease (PAD) Therapeutics Market - Key Trends and Drivers Summarized

Peripheral Artery Disease (PAD) is a widespread health issue, especially among individuals over 40 years old, including those with diabetes mellitus and smokers, with about 7.2 million affected in the U.S. alone. PAD significantly impacts quality of life through reduced mobility and pain, and increases mortality risk due to its connection with atherosclerotic disease. It varies in manifestation from asymptomatic cases to severe limb ischemia characterized by pain and ulcers. Despite often being symptom-free, asymptomatic patients still exhibit decreased functional capacity and face similar ischemic risks as those with symptoms, underlining the need for comprehensive strategies that tackle both symptoms and underlying atherosclerotic risks.

Treatment advancements in PAD have focused on multi-pronged approaches that reduce cardiovascular risks and manage claudication symptoms and tissue loss in critical cases. However, the lack of specific PAD-focused evidence has led to reliance on extrapolated data from other cardiovascular conditions. Common treatments include statins, antiplatelets, and angiotensin-converting enzyme inhibitors, largely supported by evidence from coronary or cerebrovascular studies. Although antiplatelet therapy is established in managing coronary diseases, its efficacy specifically for PAD is less certain, indicating a need for PAD-specific research to refine treatment guidelines. Meanwhile, for asymptomatic cases, antiplatelet therapies like aspirin and clopidogrel are recommended despite debates over their effectiveness, highlighting an ongoing investigation into their comprehensive benefits.

Significant growth drivers in the PAD therapeutics market include technological advancements in diagnostic imaging, like duplex ultrasound and magnetic resonance angiography, which enhance early and accurate disease detection. The rising prevalence of lifestyle diseases such as diabetes and obesity also escalates PAD cases, boosting demand for effective treatments. Increased public and medical awareness through educational campaigns and screening programs, along with innovations in drug development and personalized medicine, are pushing the boundaries of traditional PAD treatment approaches. Moreover, the trend towards minimally invasive procedures, expansion of drug indications originally developed for other cardiovascular conditions, and evolving healthcare policies and reimbursement scenarios are reshaping treatment paradigms, fostering greater adoption of novel therapeutics in the management of PAD.

Select Competitors (Total 32 Featured) -

• AstraZeneca Plc.
• Bayer HealthCare Pharmaceuticals
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Proteon Therapeutics, Inc.
• Sanofi S.A.
• Symic Bio, Inc.
• TheraVasc, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.